Preprint
Brief Report

This version is not peer-reviewed.

West Nile Virus Lineage 2 Neuroinvasive Infection Presenting as Intraparenchimal Cerebral Hemorrage

Submitted:

15 December 2025

Posted:

16 December 2025

You are already at the latest version

Abstract
Objective: The aim of this retrospective study was to evaluate clinical and laboratory characteristics in adult patients with neuroinvasive West Nile virus (WNV) infections. We also studied the phylogeny and molecular characteristics of some of the WNV strains. Methods: A retrospective analysis was conducted at “Annunziata” Hub Hospital, a secondary referral facility in Calabria region in Southern Italy. Patients with confirmed WNV infection were included in the study. Biochemical and serological analysis of blood and cerebrospinal fluid (CSF), as well as radiological imaging were done. Sample pre-processing, sequencing and bioinformatic analyses were carried out at IRCCS Sacro Cuore Don Calabria Hospital in Negrar di Valpolicella, Verona, Veneto region in North-East Italy. All the analyses were performed on the same whole blood samples used for the laboratory diagnosis. Results: 9 cases of West Nile encephalitis (WNE) were analyzed, involving 8 males and 1 female, with a mean age of 70.33 years (Range, 60 – 85). Encephalitis was confirmed by the demonstration of specific IgM and IgG antibodies in serum using routine serological screening tests. All the patients had specific IgM antibodies at admission and IgG antibodies were present in 90%. The overall average hospital stay was 20.6 days (range, 6 – 46). Six patients made a full recovery with no neurological sequelae after a meanof 35.3days of acute care.30-day mortality rate was 23%. A 63-year-old man developed a fulminat Guillain-Barré syndrome (GBS) and he died after approximately two months because of severe respiratory complications. Two male patients died after 21 and 13 days, respectively, due to intraparenchimal cerebral hemorrage (ICH) as clinical presentation of WNV encephalitis. A third male patient presented with encephalitis and cauda equina syndrome, complicated by diffuse ICH and a concomitant extensive epidural hematoma. This patient was transferred to a rehabilitation long-term care facility and is still alive after a three-month ‘ follow-up, although he is no longer able to walk. Finally, a 66-year-old male patient presented a severe right Bell’s palsy regressing very gradually in about two months. Phylogenetic analysis shows that our sequences are closely related to other southern-Italian and cluster with Central-Southern-Eastern European sequences, while being evidently separated from northern-Italian and Central-Western European ones, belonging to the sub-lineage 2a of the WNV-2, clustering with sequences from the Central-South-Eastern clade, mainly to Hungary. Conclusions: Cerebrovascular complications of WNE may be an important clinical manifestation of WNV neuroinvasive infection. Preliminary data do not allow us to determine whether our strains, closely related to other southern-Italian and cluster with Central-Southern-Eastern European sequences, really presented an increased neurovirulence.
Keywords: 
;  ;  ;  ;  ;  ;  

1. Introduction

Most West Nile Virus (WNV) infections are asymptomatic, mild, or undiagnosed; however, severe cases of WNV neuroinvasive disease are incresingly reported, probably related to WNV's specific affinity for the nervous system, both central and peripheral. West Nile encephalistis (WNE) presents as severe neuroinvasive disease after a flu-like prodrome, featuring rapid progression to neurological issues, like acute flaccid paralysis, movement disorders, altered mental status, seizures, and neck stiffness, affecting under 1% of WNV-infected individuals [1].
WNE involves brain inflammation, but it can also trigger cerebrovascular issues like vasculitis and strokes, both ischemic and/or hemorrhagic, making it mimic a stroke or cause stroke-like symptoms. This neuroinvasive form (<1% of cases) damages blood vessels, leading to these serious complications, even causing intracranial cerebral hemorrage (ICH), expanding the range of severe WNV neurological impacts beyond typical clinical features [2].
Cerebral haemorrhage is a leading cause of death worldwide and an important health issue. Although common causes predominantly affect the elderly, there exists a spectrum of uncommon etiologies that contribute to the overall incidence of intracerebral hemorrhage[3].
Infectious causes of ICH may involve organisms like bacteria (Streptococcus pneumoniae, syphilis), viruses (HIV, VZV, HSV, COVID-19), fungi (Aspergillus, Cryptococcus), and parasites, leading to inflammation (vasculitis), ruptured aneurysms, or clotting issues (coagulopathy) that damage blood vessels, causing them to leak or burst, as seen in tuberculous meningitis, endocarditis, or invasive fungal infections.

2. Methods & Results

We conducted a descriptive study of cases of WNV neuroinvasive infections occurred between 2023 and 2025 in the province of Cosenza coverinh a large territory in Calabria, a region of Southern Italy, in order to evaluate unusal clinical presentations.
9 cases of neuroinvasive WNV infections were analyzed, involving 8 males and 1 female, with a mean age of 70.33 years (Range, 60 – 85) (Table 1). WNE was confirmed by the demonstration of specific IgM and IgG antibodies in serum using routine serological screening tests. Laboratory diagnosis of WNND was carried out at the “Annunziata” Hub Hospital, Cosenza. Cerebrospinal fluid (CSF) and blood sample were analyzed for WNV infection using the one-step real time RT-PCR (kit WNV ELITe MGB®️ Kit (ELITechGroup SAS, Puteaux, France), following the manufacturer’s instructions. All patients had specific IgM antibodies at admission and IgG antibodies were present in 90%.
The overall average hospital stay was 20.6 days (range, 6 – 46). Six patients made a full recovery with no neurological sequelae after a meanof 35.3days of acute care.30-day mortality rate was 23%. A 63-year-old man developed a fulminat Guillain-Barré syndrome (GBS) responsible for a severe tetraparesis and a respiratory failure, requiring a tracheostomy and initial intubation. He was transferred to a rehabilitation long-term care facility 46 days after hospital admission, but he died after approximately two months, because of severe respiratory complications.
Three male patients with a median age of 71 years (range, 68-74), presented ICH associated with WNE. Two male patients, the first 74-year-old suffering from arterial hypertension and the second 68-year-old suffering from diabetes mellitus and post-ischemic dilated heart disease,died after 13 and 21 days, while the third patient was transferred to a neuromotor rehabilitation facility after 34 days of hospitalization. This patient, before admission to the hospital, presented age-related brain involution symptoms and suffered from chronic hypertensive heart disease. The reasons for admission to the Emergency Room were worsening motor difficulties with weakness in the lower limbs, a rapidly worsening state of confusion, high fever, and an episode of hypertensive peak.Repeated studies of the brain and spinal cord, using CT scans and MRI, have documented a very complex picture, characterized by diffuse meningoencephalitis, with a diffuse flogistic involvement of the pachy-leptomeninges and the equine cauda roots,blood deposits in the occipitopolar and bihemispheric mid-posterior cingulate sulci, the left temporoparietal carrefour, the fourth ventricle and occipital horns and the pericerebellar cistern. There was evidence also of a diffuse posterior dorso-lumbo-sacral, anterior dorso-lumbar (up to L1) and sacral spinal cord epidural hematoma. Diffuse hemosiderin coating were present on the dural surface in the dorso-distal posterior lumbo-sacral and anterior lumbo-sacral regions, as well as at the anterior 8th-10th level. Serology for WNV was positive, while WNV RNA testing in CSF, blood, and urine was negative. Treatment included two 5-day cycles of high-dose immunoglobulins and the use of dexamethasone.
The second patient was a 68-year-old man with diabetes mellitus and post-ischemic dilated heart disease, admitted to the emergency room for a syncope in absence of cardiac arrhythmias.
The patient appeared drowsy, but initially arousable. A spinal tap was not performed urgently due to concomitant aspirin therapy. A brain CT scan documented an increase in the volume of the subarachnoid spaces of the vault and skull base, thin, hygromatous subdural hypodense layers in the bilateral frontal lobe, and a blood hyperdensity within the right subdural collection in the right frontotemporal parietal lobe. An EEG revealed slow background activity in the theta and delta bands, with low voltage, and slightly asymmetric (right greater than left). Serology for WNV was positive and urine WNV-RNA testing was positive with a titer of 1072 copies/mL.
The patient received both high-dose immunoglobulin for seven days and dexamethasone, but his clinical condition did not change, resulting in death 13 days after hospital admission.
The third patient was a 74-year-old male suffering from hypertensive heart disease, hospitalized for high fever, worsening spatial-temporal disorientation and mental confusion, associated with dysarthria. There was evidence of a left upper limb paresis. An EEG revealed a widespread slowing of brain bioelectrical activity to 4-5 c/s, interspersed with additional bursts of spike waves over the left frontotemporal regions, which spread to the contralateral hemisphere. Both a CT scan and a brain MRI documented subdural hygromatous collections along the bilateral fronto-temporo-parietal convexities. Despite treatment with high-dose immunoglobulin for 5 days and dexamethasone, the clinical conditions worsened, resulting in death 21 days after hospital admission.
Finally, a 66-year-old male patient presented a severe right Bell’s palsy regressing very gradually in about two months. The Bell’s palsy regressed very gradually, after treatment with immunoglobulins and dexamethasone, in about two months, leaving no remnants and without relapse at the three-month follow-up. The remaining four patients presented with moderate severity of WNE, responded positively to treatment with immunoglobulins and dexamethasone and were discharged with complete recovery. In our small cohort, we observed two other cases of patients with an unusual presentation. A 66-year-old male patient presented with severe right Bell's palsy, which gradually regressed over approximately two months. This patient was treated with both steroids and immunoglobulins. Steroid treatment was continued with tapering doses for approximately six weeks. This is the first patient with WNV-related facial palsy to be treated simultaneously with steroids and immunoglobulins, with a complete clinical response.
A recent systematic review of case reports on WNV infection-associated cranial nerve neuropathy, reported 13 cases of facialsy palsy related to WNV infection. Thus facial palsy represented 31.0% of 42 cases of cranial nerve neuropathies as an outcome of WNV infection, reported in 30 case reports. The mean time until onset of signs and symptoms of facial palsy was 1–16 days.
Complete recovery was significantly associated with absence of comorbidities, while it is difficult to establish the role of the use of antivirals, steroids and antibiotics, variously used in combination without a precise criterion. However, it is also true that three male patients aged 57, 45, and 27 who did not receive antivirals did not achieve resolution of facial palsy. Furthermore, a 34-year-old man with involvement of the VII and XI cranial nerves, treated with antibiotics, achieved only partial improvement.
We investigated the phylogeny and molecular characteristics on the complete genome sequence of the GBS case, identified in September 2023 (WNV-2-Cal/2023), as well as the complete genome sequences of two of the patiente with ICH ascociated WNE in august 2024.
The analysis included sequences from the GenBank database, ranging from the first European/African sequences deposited up to September 2025. The majority of sequences originate from Italy (n=124), Greece (n=112), Germany (n=99), Russia (n=87), and Hungary (n=76), primarily associated with mosquito (~36%), humans (~29%), and birds (~27%) hosts.
Sample pre-processing, sequencing and bioinformatic analyses were carried out at IRCCS Sacro Cuore Don Calabria hospital in Negrar di Valpolicella, Verona. All the analyses were performed on the same whole blood samples used for the laboratory diagnosis.
The whole blood samples' nucleic acid content was extracted via Qiagen EZ1 Advanced XL, with the EZ1 ® DSP Virus kit, from 200uL into 60uL (Qiagen, Hilden, Germany). RNA was quantified using the Qubit RNA HS assay kit (Invitrogen, Thermo Fisher Scientific, Inc., Waltham, MA, USA) and the High Sensitivity RNA ScreenTape on the 4200 TapeStation System (Agilent Technologies Inc., Santa Clara, CA, USA).
Full-length WNV genome sequences were obtained using two different approaches: (i) the Illumina RNA prep kit with enrichment, with Viral Surveillance Panel (VSP) hybridization capture probes (Illumina, California, USA), following the manufacturer's instructions; and (ii) a panel of tiled amplicons of 400bp in length (Diagne et al., 2023). Amplicons underwent Illumina DNA prep kit processing, as per manufacturer instructions. Libraries were loaded on Illumina P1 flow cells (Illumina, California, USA), running 2x150bp, on a NextSeq1k. Each library was evaluated via qubit DNA HS and High Sensitivity DNA ScreenTape 5000 prior to loading on the appropriate flow cell.

3. Discussion

A comprehensive search was conducted across the PubMed, Scopus, Web of Science, and Embase databases to extract relevant published data existing about ICH and WNE, up to November 2025. This retrospective analysis reveled only three reported cases of ICH in WNE patients (Table 2).
A case of severe, bilateral necrotizing and hemorrhagic encephalitis was reported in a 43-year-old man, undergoing mycophenolate mofetil therapy for a renal transplant due to diabetes mellitus. He died 12 days after hospital admission. Autopsy revealed predominantly inflammatory involvement of motor neurons and a positive immunohistochemical staining for WNv antigen [4].
Castaldo N et al. [5] documented in 2020, a 57-year-old male patient suffering from autoimmune glomerulopathy, treated with immunosuppressive therapy, with rhombencephalitis and massive intraparenchymal hemorrhage, fourth ventricle compression and tonsillar herniation. He died 5 days after admission [4].
Harroud A et al. [2] described a 73-year-old female patient with lymphocytic encephalitis and subarachnoid hemorrhage. She was treated with supportive care and he was discharged in improved clinical condition, able to walk without support, but with chronic cognitive deficits.
Our review highlighted nine cases of ischemic and hemorragic stroke associated with WNV infection reported in the literature [6,7,8,9,10,11,12,13] (Table 2).
Seven patients were female and two were male, with a median age of 49.22 years (range, 7–74). The outcome was favorable, being all but one patient discharged, with no residual neurological findings and no recurrences in subsequent follow-up. Only one patient died due to severe acute respiratory failure during the ICU stay. Comorbidities were varied; only one of these patients had a confirmed history of recurrent cerebral ischemic episodes. Tangella N et al. reported a case of acute ischemic stroke and subaracnoid hemorrage (SAH) [12], while Lowe LH et al. [7] described three pediatric cases of primary idiopathic cerebral vasculitis complicated by stroke. These cases were observed in three girls aged 7, 9, and 12 years and were followed by complete recovery with a regimen of aspirin, steroids, and cyclophosphamide. In all three of these children, during follow-up up to 36 months, 19 months, and 18 months, respectively, no recurrence of stroke was detected, and the neurological condition was stable [7].
A recent systematic review [14] of case reports on WNV infection-associated cranial nerve (CN) neuropathy, reported 13 cases of facialsy palsy related to WNV infection.Thus facial palsy represented 31.0% of 42 cases of cranial nerve neuropathies as an outcome of WNV infection, reported in 30 case reports. The mean time until onset of signs and symptoms of facial palsy was 1–16 days [14].
Complete recovery was significantly associated with absence of comorbidities, while it is difficult to establish the role of the use of antivirals, steroids and antibiotics, variously used in combination without a precise criterion. However, it is also true that three male patients aged 57, 45, and 27 who did not receive antivirals did not achieve resolution of facial palsy. Furthermore, a 34-year-old man with involvement of the VII and XI cranial nerves, treated with antibiotics, achieved only partial improvement.
A 63-year-old man developed a GBS unresponsive to steroids, immunoglobulins and plasmaferisis. This patient died after approximately two months after hospital admission, because of severe respiratory complications.
Neuroinvasive WNV disease presenting as GBS or Guillain-Barré–like syndrome (GBLS) has been increasingly reported [25,26,27,28,29,30,31,32,33,34,35] (Table 4).
A polio-like syndrome with paralysis involving one (monoparesis) to four limbs (tetraparesis), with or without brainstem involvement and respiratory failure, has been described. This syndrome of acute flaccid paralysis may occur without overt fever or meningoencephalitis. Although involvement of the anterior horn cells of the spinal cord and motor neurons of the brainstem are the main sites of pathology responsible for neuromuscular signs, inflammation may also involve the skeletal and/or cardiac musculoskeletal system (myositis, myocarditis), motor axons (polyradiculitis), and peripheral nerves (GBS), or present as brachial plexopathy. Furthermore, involvement of spinal sympathetic neurons and ganglia provides an explanation for the autonomic instability observed in some patients. Many patients also experience prolonged subjective generalized weakness and disabling fatigue. The long-term outcome of WNV polio-like syndrome appears to be more heterogeneous than preliminary data may have suggested, with some patients showing little neurologic and functional improvement and others showing substantial improvement. The degree of initial weakness appears to be a predictor of subsequent long-term outcome. the CDC reports that 13% of WNV infections manifest as GBS [36].
In most of the cases reported from currente literature through a PUBMED/MEDLINE search summarized in Table 4, gradual and slow improvement occurred, often with residual neurologic deficits of varying severity. Treatment includes supportive care and consideration of the use of intravenous immunoglobulin and, if unsuccessful, plasmapheresis [25,26,27,28,29,30,31,32,33,34,35,36].
Phylogenetic analysis showed that the WNVIRCCS-SCDC_01/2025 strain (WNV2-Cal/2023) and the other two strains analysed belonged to the sub-lineage 2a of the WNV-2, clustering with sequences from the Central-South-Eastern clade (Figure 1). The neighboring branches reported sequences from the Southern and Eastern Europe, such as Greece, Hungary, Serbia, Russia, Romania, Slovakia, Poland and Kosovo. In particular, the most closely related sequences could be traced back mainly the WNV Hungary 578/10 strain (GenBank accession ID: KC496015.1). The polyprotein sequence analysis of the WNV-2 strains from Calabria region identified non-synonymous substitutions that were representative signatures in the genome-based phylogenetic analysis of Hungarian clade of WNV-2 Central-South-Eastern cluster. In particular, the WNV-2 genomes detected in the Calabria region were characterized by amino acid residues (NS2B-V119I, NS3-H249P, NS4B-S14G, and NS4B-T49A) that were not present in other sequences of the Central-North-Western Europe (including them from NC-Italy). These observed residues were shared with the Central-South-Eastern European WNV reference strain (Hungary 578/10), isolated in 2010 (NS2B-119I, NS3-249P, NS4B-14G, and NS4B-49A). Moreover, among these substitutions, the Proline at NS3-249, was previously associated with higher neurovirulence. Preliminary data do not allow us to determine whether our strains presented an increased neurovirulence, potentially attributable to some amino acid substitutions located in the Envelope protein. However additional investigations and data consolidation are necessary to clarify this point. Most WNV infections are asymptomatic, mild, or undiagnosed; however, severe cases of WNV neuroinvasive disease are incresingly reported, probably related to WNV's specific affinity for the nervous system, both central and peripheral. WNV infection can rarely cause cerebral vasculitis, a serious inflammation of brain blood vessels, leading to complications like ischemic or hemorrhagic stroke and severe neurological issues [2]. This viral vasculitis may involve direct viral infection of endothelial cells, causing vessel damage, rupture, and subsequent bleeding or blockage. Clinicians should suspect WNV in ischemic and hemorragic stroke cases during summer and mosquito season, especially with cerebral hemorrhagic signs. We suggest that clinicians should be vigilant for vasculitic complications in WNV patients, including ICH.
Table 2. Neuroinvasive West Nile Virus infections presenting as ischemic or hemorragic stroke.
Table 2. Neuroinvasive West Nile Virus infections presenting as ischemic or hemorragic stroke.
References, Country,type of article Age (y), sex Comorbidity Clinical features Head CT EMG Head MRI Clinical diagnosis Autopsy findings Treatment Outcome
Smith RD et al., University of Cincinnati, USA, 2024 43, M Renal allograft, end-stage
renal disease from diabetes mellitus
A 2-day history of nausea, vomiting, diarrhea, and chills
with fever
Bilateral thalamic edema extending to the midbrain and
pons
NR Extensive edema involving the pons,
medulla, midbrain, and bilateral thalami as well as the medial
left temporal lobe
A severe, bilateral, necrotizing and hemorrhagic encephalitis
preferentiallving motor neurons. Immunohistochemistry search
for WNV antigen was positive
Acyclovir
therapy, and discontinuation of the immunosuppressive regimen (Micophenolate)
Died
12 days after hospital admission.
Whitney EA et al., Emory University, Atlanta,
USA, 2006
68, F Recurrent transient
ischemic attacks, peripheral vascular disease,
seizures
High fever,
cough,
losing of balance and falling easily when
walking
Non-revealing NR Unremarkable Community-acquired pneumonia, atrial fibrillation,
and cerebellar stroke
Oral antibiotics, carbamazepine. Discharged on the 7th day
Peters S & Brown K, University
of Calgary, Canada, 2021
57, M None Pharyngitis and a descending
maculopapular rash on the torso, arms, legs, and feet including
the palms. Right
hemiplegia, aphasia.
“T” occlusion of the distal left internal carotid artery NR Patchy infarction in the left insula, basal ganglia, and
operculum
Acute cryptogenic stroke Intravenous thrombolysis,
endovascular
thrombectomy, intra-arterial verapamil
Discharged with no residual neurologic deficits and no recurrence after two
years later
Kulstad EB, Wichter MD, Advocate Christ Medical Center,
Oak Lawn, Illinois, USA, 2003
70, M Chronic lymphocytic leukemia Mental confusion,
dysarthria, pronation of the right upper limb,
external rotation of the right lower limb, ascending Babinski reflex
Mild atrophy consistent with
the patient’s age, some mild
chronic ischemic changes in the
periventricular white matter
NR Mild chronic ischemic demyelination
with several small lacunar
infarcts, but no acute changes
Stroke
with rhabdomyolysis and acute renal
failure
Oxygen, fluid hydration,
intubation.
Death
on hospital day 10 because of respiratory failure in ICU
Alexander JJ et al.,
University of Missouri,Kansas City, USA, 2006
9, F Environmental exposure to mosquitoes
Intermittent right arm and leg weakness. She fell from her bicycle and developed
transient aphasia
A small hypodense area in the left anterior temporal lobe NR Increased T 2-
weighted signal in the left caudate nucleus, lentiform nucleus, and left
anterior temporal region. Bilateral irregularities of the distal middle
cerebral arteries, left posterior cerebral artery, and left
middle cerebral artery
Stroke Associated With Central Nervous System
Vasculitis After West Nile Virus Infection
She was initially treated with hydration, low-dose
aspirin, and verapamil.
Methylpredni-
solone was started on the 3rd day for probable
vasculitis.
Five monthly doses of cyclophosphamide began with a
moderate improvement in right motor
function
Discharged. Clinical
improvement 18 months later.M ild left brain volume loss, persistent middle cerebral artery
asymmetry, a small left M1 mainstem trunk, and attenuated distal sylvian
branches were present in the follow-up
Castaldo N et al. Udine University, Italy, 2020 57, M Autoimmune glomerulonephritis in immunosuppressive treatment Fever, confusion, diplopia, opsoclonus, multifocal myoclonus and generalized tremor. Massive intraparenchymal hemorrhage, fourth ventricle compression and tonsillar herniation Slow bilateral diffuse slow waves Unremarkable Rhombencephalitis,
coma, intracranial
hemorrhage
Macroscopic examination of the brain showed diffuse malacia Empirical therapy with ampicillin, ceftriaxone, acyclovir and dexamethasone. Therefore, IVIGs and steroids. Died 5 days after admission
Jacob S et al., Mayo Clinic, Phoenix, Arizona, USA,
2019
67, F None. Significant history of pigeon exposure Right sided facial droop, right sided weakness, low back pain, fever and lethargy Unremarkable N.A. Medial left frontal acute infarct Stroke with encephalopathy IVIG Her
mental status significantly improved and she was discharged to a rehabilitation facility.
Harroud A et al., Montreal Neurological Hospital and McGill University, Montreal, Canada, 2019 73, F A remote history of renal cell and breast carcinomas, both in complete remission and no
treatment.
Confusion, high fever. decreased level of
consciousness and aspiration pneumonia requiring intubation. On day 8, the patient developed generalized myoclonus
Unremarkable Severe slowing but no epileptic activity Extensive
and confluent leukoencephalopathy and interval appearance of bilateral convexity.
SAH
Encephalitis with
lymphocytic pleocytosis and myoclonus
Supportive treatment including neurointensive
care monitoring and IV hydration
On discharge, the
patient was able to walk without support but suffered from
residual cognitive deficits
Hingorani K et al., Boston Medical Center, Massachusetts, USA, 2023 70, F None Depressed level of consciousness,
hypophonia
Bilateral corona radiata strokes Mild generalized delta slowing Bilateral corona radiata strokes Stroke NR Discharged
Tangella N et al., Rutgers The State University of New Jersey, USA, 2023 74, M ESRD, T2DM,
DDRT, prostate cancer.
3-4 days of nausea, vomiting, diarrhea, fever and chills NR Diffuse
slowing
Acute ischemic stroke and SAH NR Empiric meningitis treatment. Therefore,
IVIG for suspected GBS
NR
Lowe LH et al.,
University of Missouri–Kansas City,USA, 2005
7, F None Headache, right hemiparesis,
aphasia, and facial droop
Unremarkable
NR Acute left middle cerebral artery
stroke
Primary cerebral vasculitis Aspirin, steroids, cyclophosphamide. Discharged, without recurrent stroke after 36 months
of clinical follow-up
Lowe LH et al.,
University of Missouri–Kansas City,USA, 2005
12, F None Headache, slurred speech,
nausea, and vomiting
Abnormality in the left
middle cerebral artery, internal carotid artery, and anterior
carotid artery distributions
NR Abnormality in the left
middle cerebral artery, internal carotid artery, and anterior
carotid artery distributions
Primary cerebral vasculitis Aspirin, steroids,
and cyclophosphamide.
Discharged, without recurrent stroke
after 18 months of clinical follow-up
Lowe LH et al.,
Missouri–Kansas City,USA, 2005
9, F None Headache,
right arm and right leg weakness, and acute aphasia
Acute left middle
cerebral artery distribution stroke
NR Acute left middle
cerebral artery distribution stroke
Primary cerebral vasculitis Aspirin, steroids, and cyclophosphamide Discharged, without recurrent stroke
after 19 months of follow-up
Abbreviations: CAD, coronary artery disease; CT, computerized tomography; DDRT, deceased donor renal transplantation; EMG, electromyography; ESRD, end stage renal disease; IVIG, intravenous immunoglobulin therapy; y, year; MRI, magnetic resonance imaging; NR, not reported; PRES, posterior reversible encephalopathy; pts, patients; SAH, subarachnoid hemorrhage; T2DM, diabetes mellitu type 2; WNV, West Nile virus.
Table 3. Neuroinvasive West Nile Virus presenting as Guillain-Barré syndrome (GBS) or Guillain-Barré–like syndrome (GBLS).
Table 3. Neuroinvasive West Nile Virus presenting as Guillain-Barré syndrome (GBS) or Guillain-Barré–like syndrome (GBLS).
References, Country,type of article Age (y), sex Comorbidity Clinical features CT scan of the brain EMG MRI of the brain / spine Treatment Outcome
Ashkin A et al, 2023, USA, case report 67, M CAD, hyperlipidemia Fever, nausea, vomiting, and right lower quadrant abdominal pain NA Nonrecordable nerve conduction velocity in bilateral peroneal nerve, a slowing of the right tibial nerve conduction velocity Not remarkable 3-day course of IVIG, 1 g of methylprednisolone daily for of 5 days Residual lower extremity weakness
Sciturro M et al., 2022, Florida, USA, case report 64, M Asthma, diverticulitis,
nephrolithiasis.
Generalized bilateral upper and lower extremity
weaknes
NA NA Not remarkable IVIG and plasmapheresis, with no improvement Died
Beshai R et al., 2020, New York, USA, case report 65, F NA Progressive ascending paralysis Normal Acute sensorimotor axonal and demyelinating peripheral neuropathy NA 10-day course of IVIG Improved, but lower extremity weakness unchanged
Paphitou NI et al., 2017, Cyprus, case report 75, M CAD, prostate cancer Reduced muscle strength
in the lower limbs
Not remarkable. Nonspecific findings of peripheral neuropathy Not remarkable 5-day course of IVIG Recovered
Walid MS et al., 2009, USA,case report 55, M Diabetes mellitus, hypothyroidism Muscle weakness
and numbness in all four extremities
Not remarkable Sensorimotor mixed polyneuropa-
thy, predominantly axonal
Not remarkable Plasma-
pheresis and dexamethasone, with no improvement. A 7-day course of IVIG with improvement
Recovered
Sejvar JJ et al., 2006, Colorado, USA,
prospective study
4 pts NA Ascending weakness with
sensory symptoms.
NA Demyelinating sensorimotor neuropathy. NA NA 1 pt lost to follow-up.
2 pts had recovery
Ahmed S et al., 2000, USA, case report 69, M Hypertension Progressive weakness, quadriparesis,
Not remarkable Demyelinating polyneuritis with secondary motor axon
degeneration
Not remarkable 5 cycles of plasmapheresis with no improvement; 2 courses of IVIG, with only minimal improvement Transferred to a nursing home with a tracheostomy and a
gastrostomy feeding tube
Joseph N et al., 2019, USA,case report 40, M Hypertension Progressive muscle
weaknes
NA Demyelinating sensorimotor polyneuropathy NA 5-day course of IVIG Recovered
Abraham A et al., 2011, USA, case report 67, F None Shoulder and back pain, generalized
weakness, fever and diarrhea
Occipital lobes hypodensities Demyelinating polyneuropathy. PRES 5-day course of
IVIG
Recovered
Abbreviations: CAD, coronary artery disease; CT, computerized tomography; EMG, electromyography; IVIG, intravenous immunoglobulin therapy; y, year; MRI, magnetic resonance imaging; NA, not available; PRES, posterior reversible encephalopathy; pts, patients; WNV, West Nile virus.
Table 4. Summary of cases of facial palsy associated with WNV infection, January 2000 to November 2025.
Table 4. Summary of cases of facial palsy associated with WNV infection, January 2000 to November 2025.
References (First author,year, country) Age (years, y), sex Medical history Clinical features Cranial nerves Treatment Outcome
Flaherty MS et al.,2003,USA 34, M CD Non-specific viral illness,tinnitus,facial palsy VII,XI Systemic antibiotics Partial recovery
Rosenheck ML et al., 2022, USA 40, F CD Facial palsy,
weakness in extremities
VII Systemic antivirals, steroids and antibiotics Cured
EL-Dokla AM et al., 2018, USA 48, M NA Facial palsy, weakness in extremities VII Systemic antivirals snd steroids Cured
EL-Dokla AM et al., 2018, USA 49, F NA Non-specific viral illness,
facial palsy
weakness in extremities
VII Systemic antivirals and steroids Cured
Sejvar JJ et al., 2003, USA 57, M CD Facial palsy
weakness in extremities
VII Supportive therapy No recovery
Li J et al.,2003,USA 45, M Healthy Facial palsy VII Immunoglobulins No recovery
Li J et al.,2003,USA 27, M CD Non-specific viral illness,facial palsy,
weakness in extremities
VII, XI NA No recovery
Al-Hashimi I et al., 2024,USA 68, F CD Non-specific viral illness,facial palsy,
diplopia,decreased shoulder shrug,
dysarthria
II,VII, XI Systemic antivirals and antibiotics Cured
Cunha BA et al.,2006,USA 47, M NA Vision problems VI,VII NA Cured
Nikolic N et al.,2024,Serbia 65, F CD Non-specific viral illness,
facial palsy,
weakness in extremities
VII Systemic antivirals and antibiotics Cured
Ostapchuk YO et al.,2020,Kazakhstan 28, M NA Non-specific viral illness,
facial palsy
weakness in extremities
VII Supportive therapy Cured
Ostapchuk YO et al.,2020,Kazakhstan 19, F NA Non-specific viral illness,facial palsy,
weakness in extremities
VII Systemic antivirals and
supportive therapy
Cured
Jhunjhunwala K et al.,2018,USA 28, F Healthy Non-specific viral illness, facial palsy,
weakness in extremities
VII Systemic antibiotics Cured
This case series 66, M CD High fever, vomiting, peripheral paresis of the VII right cranial nerve VII Steroids, Igs Cured
Abbreaviations: CD, chronic disease; CNs, cranial nerves; F, female; M, male; NA, not available.

Author Contributions

Conceptualization, A.M. (Antonio Mastroianni), S.G., and C.C.; methodology, A.M. (Antonio Mastroianni), S.G..; investigation C.C.; S.G.; A.M. (Antonio Mori), S.M.; writing—original draft preparation, A.M. (Antonio Mastroianni), S.G., C.C.; writing—review and editing, A.M. (Antonio Mastroianni), S.G., C.C.; supervision, A.M. (Antonio Mastroianni), C.C.; All authors have read and agreed to the published version of the manuscript.During the preparation of this manuscript/study, the authors do not used any material that has been generated by GenAI tools. Authors are fully responsible for the originality, validity, and integrity of the content of their manuscript.

Funding

The authors declare no funding was received for conducting this case study.

Conflicts of Interest statement

The authors declare no conflict of interest.

Patient’s consent

The patient described in the current manuscript have not been reported in any other submission. The case study was approved by the Local Advisory Board.

Ethical Consideration

The information contained in this manuscript complies with the journal’s ethical standards.

References

  1. Solomon, T.; Ooi, M.H.; Beasley, D.W.; Mallewa, M. West Nile encephalitis. BMJ 2003, 326, 865–869. [Google Scholar] [CrossRef] [PubMed]
  2. Harroud, A.; Almutlaq, A.; Pellerin, D.; Paz, D.; Linnell, G.J.; Gendron, D. West Nile virus-associated vasculitis and intracranial hemorrhage. Neurol Neuroimmunol Neuroinflamm 2019, 7, e641. [Google Scholar] [CrossRef]
  3. Chutinet, A.; Charnnarong, C.; Suwanwela, N.C. Stroke from Infection. Cerebrovasc Dis Extra 2025, 15, 118–129. [Google Scholar] [CrossRef]
  4. Smith, R.D.; Konoplev, S.; DeCourten-Myers, G.; Brown, T. West Nile virus encephalitis with myositis and orchitis. Hum Pathol. 2004, 35, 254–258. [Google Scholar] [CrossRef]
  5. Castaldo, N.; Graziano, E.; Peghin, M.; Gallo, T.; D'Agaro, P.; Sartor, A.; Bove, T.; Cocconi, R.; Merlino, G.; Bassetti, M. Neuroinvasive West Nile Infection with an Unusual Clinical Presentation: A Single-Center Case Series. Trop Med Infect Dis. 2020, 5, 138. [Google Scholar] [CrossRef] [PubMed]
  6. Kulstad, E.B.; Wichter, M.D. West Nile encephalitis presenting as a stroke. Ann Emerg Med. 2003, 41, 283. [Google Scholar] [CrossRef] [PubMed]
  7. Lowe, L.H.; Morello, F.P.; Jackson, M.A.; Lasky, A. Application of transcranial Doppler sonography in children with acute neurologic events due to primary cerebral and West Nile vasculitis. AJNR Am J Neuroradiol. 2005, 26, 1698–1701. [Google Scholar]
  8. Whitney, E.A.; Heilpern, K.L.; Woods, C.W.; Bahn, C.C.; Franko, E.A; Del Rio, C.; Silk, B.J.; Ratcliff, J.J.; Bryant, K.A.; Park, M.M.; et al. West Nile virus among hospitalized, febrile patients: a case for expanding diagnostic testing. Vector Borne Zoonotic Dis. 2006, 6, 42–49. [Google Scholar] [CrossRef]
  9. Alexander, J.J.; Lasky, A.S.; Graf, W.D. Stroke associated with central nervous system vasculitis after West Nile virus infection. J Child Neurol. 2006, 21, 623–625. [Google Scholar] [CrossRef]
  10. Jacob, S.; Taylor, A.; Kumar, G.; Patron, R.; Grill, M. A Bird Whisperer’s Tale: The unique occurrence of stroke as a precursor to diagnosing West Nile Meningoencephalitis (P4.9-017). Neurology 2019, 92(15_supplement), P4.9–017. [Google Scholar] [CrossRef]
  11. Peters, S.; Brown, K. Acute Cryptogenic Stroke During West Nile Virus Infection: Case Report. Neurohospitalist 2021, 11, 62–65. [Google Scholar] [CrossRef]
  12. Tangella, N.; Lam, E.; Rezai, F.; Burke, E. A Rare Case of West Nile Virus Associated Subarachnoid Hemorrhage. Am J Respir Crit Care Med. 2023, 207, A3528. [Google Scholar]
  13. Hingorani, K.; Feske, S.; Cervantes-Arslanian, A.M. Concomitant West Nile Virus Encephalitis and Ischemic Strokes – A Case Report and Review of the Literature (P8-10.004). Neurology 2023, 100((17_), 3487. [Google Scholar] [CrossRef]
  14. Abu-Hammad, A.; Alshamasneh, L.; Abu-Hammad, O.; Albdour, B.; Maraqa, I.; Alkhader, M.; Al-Fatafta, D.; Dar-Odeh, N. Patterns and characteristics of cranial nerve neuropathy in West Nile virus infection: a systematic review of cases reported globally. BMJ Open. 2025, 15, e104855. [Google Scholar] [CrossRef]
  15. Flaherty, M.L.; Wijdicks, E.F.M.; Stevens, J.C. Clinical and Electrophysiologic Patterns of Flaccid Paralysis Due to West Nile Virus. Mayo Clin Proc. 2003, 78, 1245–1248. [Google Scholar] [CrossRef]
  16. Rosenheck, M.S.; Higham, C.; Sanzone, K. New-onset Bell’s palsy after neuroinvasive West Nile virus. BMJ Case Rep. 2022, 15, e249770. [Google Scholar] [CrossRef]
  17. El-Dokla, A.M.; Hasan, R.; Ali, S.T. Unilateral faciobrachial weakness: An unusual neuromuscular presentation Of West Nile Virus infection. Muscle and Nerve 2018, 57, E110–2. [Google Scholar] [CrossRef]
  18. Sejvar, J.J.; Leis, A.A.; Stokic, D.S. Acute Flaccid Paralysis and West Nile Virus Infection. Emerg Infect Dis. 2003, 9, 788–793. [Google Scholar] [CrossRef] [PubMed]
  19. Li, J.; Loeb, J.A.; Shy, M.E. Asymmetric flaccid paralysis: A neuromuscular presentation of West Nile virus infection. Ann Neurol. 2003, 53, 703–710. [Google Scholar] [CrossRef] [PubMed]
  20. Al-Hashimi, I.; Okon, E. West Nile Virus: A Neglected Cause of Bell’s Palsy? Cureus 2024, 16, e62486. [Google Scholar] [CrossRef]
  21. Cunha, B.A.; Eisenstein, L.E.; Wirkowski, E. West Nile encephalitis relapse presenting with abducens and facial nerve palsies. Am J Med. 2006, 119, e1–2. [Google Scholar] [CrossRef] [PubMed]
  22. Nikolić, N.; Filipović, A.; Todorović, N. Bilateral facial nerve palsy in a patient with West Nile neuroinvasive disease. J Infect Dev Ctries. 2024, 18, 1957–1961. [Google Scholar] [CrossRef]
  23. Ostapchuk, Y.O.; Zhigailov, A.V.; Perfilyeva, Y.V. Two case reports of neuroinvasive West Nile virus infection in the Almaty region, Kazakhstan. IDCases 2020, 21, e00872. [Google Scholar] [CrossRef]
  24. Jhunjhunwala, K.; Venkatesh, Y. Neuroinvasiveness of West Nile Virus: A Case Report (P6.013). Neurology (ECronicon) 2018, 90. [Google Scholar] [CrossRef]
  25. Sejvar, J.J.; Bode, A.V.; Marfin, A.A.; Campbell, G.L.; Pape, J.; Biggerstaff, B.J.; Petersen, L.R. West Nile Virus-associated flaccid paralysis outcome. Emerg Infect Dis. 2006, 12, 514–516. [Google Scholar] [CrossRef] [PubMed]
  26. Srichawla, B.S.; Manan, M.R.; Kipkorir, V.; Dhali, A.; Diebel, S.; Sawant, T.; Zia, S.; Carrion-Alvarez, D.; Suteja, R.C.; Nurani, K.; Găman, M.A. Neuroinvasion of emerging and re-emerging arboviruses: A scoping review. SAGE Open Med. 2024, 12, 20503121241229847. [Google Scholar] [CrossRef]
  27. Ashkin, A.; Saccone, N.; Valle, J.; Rasnake, M. Symmetric Ascending Paralysis Secondary to West Nile Virus. Case Rep Neurol. 2023, 15, 120–125. [Google Scholar] [CrossRef] [PubMed]
  28. Sciturro, M.; Rehl, S.; Klingensmith, J. A Rare Case of Neuroinvasive West Nile Virus in Florida Presenting As Guillain Barré Syndrome. Cureus 2022, 14, e33138. [Google Scholar] [CrossRef]
  29. Beshai, R.; Bibawy, D.; Bibawy, J. Guillain-Barré Syndrome Secondary to West Nile Virus in New York City. Case Rep Infect Dis. 2020, 2020, 6501658. [Google Scholar] [CrossRef]
  30. Ahmed, S.; Libman, R.; Wesson, K.; Ahmed, F.; Einberg, K. Guillain-Barré syndrome: An unusual presentation of West Nile virus infection. Neurology 2000, 55, 144–146. [Google Scholar] [CrossRef]
  31. Joseph, N.; Piccione, E.A. Guillain–Barre Syndrome Triggered by West Nile Virus. Journal of Clinical Neuromuscular Disease 2019, 54–56. [Google Scholar] [CrossRef] [PubMed]
  32. Abraham, A.; Ziv, S.; Drory, V.E. Posterior reversible encephalopathy syndrome resulting from Guillain-Barré-like syndrome secondary to West Nile virus infection. J Clin Neuromuscul Dis. 2011, 12, 113–117. [Google Scholar] [CrossRef] [PubMed]
  33. Paphitou, N.I.; Tourvas, A.; Floridou, D.; Richter, J.; Tryfonos, C.; Christodoulou, C. The first human case of neuroinvasive West Nile virus infection identified in Cyprus. J Infect Public Health 2017, 10, 891–893. [Google Scholar] [CrossRef] [PubMed]
  34. Walid, M.S.; Mahmoud, F.A. Successful treatment with intravenous immunoglobulin of acute flaccid paralysis caused by west nile virus. Perm J. 2009, 13, 43–46. [Google Scholar] [CrossRef]
  35. Paphitou, N.I.; Tourvas, A.; Floridou, D.; Richter, J.; Tryfonos, C.; Christodoulou, C. The first human case of neuroinvasive West Nile virus infection identified in Cyprus. J Infect Public Health 2017, 10, 891–893. [Google Scholar] [CrossRef]
  36. Centers for Disease Control and Prevention (CDC). Acute flaccid paralysis syndrome associated with West Nile virus infection--Mississippi and Louisiana, July-August 2002. MMWR Morb Mortal Wkly Rep. 2002, 51, 825–828. [Google Scholar]
Figure 1. Phylogenetic analysis of WNV lineage 2 whole-genome sequences. In this sub-selection only European sequences were included. Red-colored labels refer to clinical cases collected at out hospital. Colored bars on the right delineate the separation between Central-Western European (blue) and Central-Southern-Eastern (red) sequences. Bootstrap values are reported where >= 90. The original tree comprises European and African sequences from the first deposited Whole-genome sequence up to August 2025. For visualization constraint, clades that contain either multiple records of the same country or low bootstrap values were collapsed. To inspect the full phylogenetic tree see: microreact.
Figure 1. Phylogenetic analysis of WNV lineage 2 whole-genome sequences. In this sub-selection only European sequences were included. Red-colored labels refer to clinical cases collected at out hospital. Colored bars on the right delineate the separation between Central-Western European (blue) and Central-Southern-Eastern (red) sequences. Bootstrap values are reported where >= 90. The original tree comprises European and African sequences from the first deposited Whole-genome sequence up to August 2025. For visualization constraint, clades that contain either multiple records of the same country or low bootstrap values were collapsed. To inspect the full phylogenetic tree see: microreact.
Preprints 189857 g001
Table 1. Clinical feature of 9 patients with WNV encephalitis admitted to our unit from 2023 to 2025.
Table 1. Clinical feature of 9 patients with WNV encephalitis admitted to our unit from 2023 to 2025.
Patient (Pt), sex, age (years,y) Comorbidity Symptoms WNV serology, IgG /IgM Urinary WNV viremia,
copies/mL
Urinary WNV viremia,
copies/mL
WNV CSF viremia, copies/ml EEG Head Tc Head MRI Treatment Complications Outcome (days)
Pt 1, F, 71, 2024 HHD, dyslipidemia Abdominal pain, fever, diarrhea, vomiting, headache +/+ < 500 3028 Neg NR UNR NR DEX None Cured, discharged after 16 d
Pt 2, M, 74, 2024 HHD High fever, confusion, disorientation, sensory clouding, headache +/+ Neg Neg Neg Slowing of cerebral bioelectrical activity with additional bursts of spike waves over the left frontotemporal regions Thin extraaxial hemorrhagic collections along the bilateral fronto-temporo-parietal convexities Thin bilateral frontoparietal subdural hemorrhagic layers DEX, Igs Left hemiparesis, progressively worsening coma Exitus, 21 days after hospital admission
Pt 3, M, 60,2024 None High fever, headache,confusion -/+ 67.067 Neg > 50.000.000 NR UNR Weak cerebellar leptomeningeal venular enhancement
DEX, Igs None Cured, discharged after 21 d
Pt 4,M, 75, 2024 CVE, H High fever, headache,confusion, dysarthria +/+ Neg Neg Neg NR UNR CVE, cerebral atrophy DEX, Igs None Cured, discharged after 9 d
Pt 5, M, 63, 2023 DM2, CHHD In the days preceding hospital admission he had suffered; upon arrival at the Emergency Room he was found to be in a coma (Glasgow Coma Scale 6), with severe weakness of the limbs and high fever +/+ Neg Neg < 500 Delta waves spread mainly over the anterior regions
EMG: severe sensorimotor polyneuropathy in the 4 limbs, of mixed type, predominantly axonal
UNR Hyperintensity in the middle cerebellar peduncles, the splenium of the corpus callosum,
and the semioval centers bilaterally
DEX, Igs, plasmapheresis Global clinical worsening with irreversible tetraparesis and mechanical ventilation through tracheostomy Transferred to a rehabilitation facility 46 days after hospital admission.Exitus after 3 week because of respiratory failure.
Pt 6, M, 84, 2024 Previous right nephrectomy for cancer, prostate cancer undergoing radiotherapy High fever, headache,confusion +/+ 842.845 9454 Neg Slowing of cerebral bioelectrical activity UNR UNR DEX, Igs None Cured, discharged after 6 d
Pt 7, M, 71, 2025 HHD, cognitive involutional syndrome High fever, headache,confusion, worsening motor difficulty with lower limb weakness +/+ Neg Neg Neg ICH of the occipital horns of the lateral ventricles. Diffuse meningoencephalitis, with involvemente of the cauda extremity roots.
ICH of the occipitopolar and bihemispheric mid-posterior cingulate sulci, the left temporoparietal carrefour, and the fourth ventricle, occipital horns, and pericerebellar cistern.
Posterior dorso-lumbo-sacral, anterior dorso-lumbar (up to L1), and sacral epidural hematoma
DEX, Igs Gradual clinical improvement, however lower limb weakness persisted Transferred to a rehabilitation facility 34 days after hospital admission.
Pt 8, M, 66, 2025 DM2, CHHD, CVE High fever, vomiting, peripheral paresis of the VII right cranial nerve +/+ Neg Neg Neg Mild diffuse encephalic suffering with slowed background electrical activity and bursts of generalized slow activity CVE CVE DEX, Igs None Cured, discharged after 20 d
Pt 9, M, 68, 2025 DM2, High fever, soporific state, poor verbal, tactile and pain reactivity +/+ Neg Neg 1072 Slow activity in the theta and delta bands, low voltage,
slightly asymmetric (right greater than left).
Bilateral frontal lobe subdural hemorrage, ICH in the right frontotemporal lobe NR DEX, Igs Overall worsening of clinical conditions and comatose state Exitus, 13 d afetr hospital admission
Abbreviations: CHHD,chronic hypertensive heart disease; CVE, chronic vasculare encephalopathy; DEX, dexamethasone; DHD, dilated heart disease;DM2, type 2 diabetes mellitus; EEG, elettroencephalophy; EMG, electromyography; H, hypertension; HHD, hypertensive heart disease; Igs, immunoglobulins; Neg, negative; NR, not reported; UNR, uremarkable; WNV, West Nile Virus.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
Prerpints.org logo

Preprints.org is a free preprint server supported by MDPI in Basel, Switzerland.

Subscribe

Disclaimer

Terms of Use

Privacy Policy

Privacy Settings

© 2025 MDPI (Basel, Switzerland) unless otherwise stated